Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02695446 · ClinicalTrials.gov registry record · Phase 4

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

A Phase 4 study of Acne, sponsored by BioPharmX.

Completed
Registry status
Phase 4
Development phase
12
Enrollment target
1
Study location

NCT02695446 is a Phase 4 study of Acne that has completed, run by BioPharmX. The registered enrollment target is 12 participants, below the 142-participant average among 26 other Acne trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02695446, a Phase 4 study of Acne, has completed, sponsored by BioPharmX.

COMPLETED
Registry status
Phase 4
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the skin and plasma concentrations of minocycline in subjects undergoing treatment of acne vulgaris with oral extended release minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.

Conditions Studied

Interventions

  • DRUG Minocycline

Study Locations (1)

Pennsylvania

  • KGL Skin Study Center - Broomall

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-03
Est. Completion 2016-05
Phase Phase 4

Sponsor

BioPharmX

6 total trials

What the Registry Record Tells You About NCT02695446

The ClinicalTrials.gov registry entry for NCT02695446 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 26 other Acne trials with a reported enrollment target (92% lower). The listed sponsor is BioPharmX, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 1 intervention - of which Minocycline is the first listed.

NCT02695446 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02695446 about?

NCT02695446 is a clinical study titled "Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline". The primary objective of this study is to evaluate the skin and plasma concentrations of minocycline in subjects undergoing treatment of acne vulgaris with oral extended release minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.

What is the current status of trial NCT02695446?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2016-03. Estimated completion is 2016-05.

What conditions does trial NCT02695446 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT02695446?

The interventions under investigation include: Minocycline (DRUG).

Who is sponsoring clinical trial NCT02695446?

This trial is sponsored by BioPharmX, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02695446 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.